Navigation Links
GeneNews restructures operations
Date:11/12/2008


- North American resources focused on commercialization of

ColonSentry(TM); Asian resources focused on pipeline development and

local commercialization -

TORONTO, Nov. 12 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: GEN), a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced that it has implemented a strategic restructuring of its North American and Asian operations. The Company's operation in Canada will focus on the Canadian and U.S. commercialization of its lead product, ColonSentry(TM), the world's first blood-based test to determine a person's current risk for colorectal cancer. Research and development of the Company's pipeline, including patient sample accrual to support these activities, will be moved to GeneNews' Asian operations. As part of the restructuring, the Company has reduced its workforce in Canada by 40%.

"While these actions are difficult, when assessing the structure of our company and our strengths in Canada and Asia, we determined that there were efficiencies in research and development that could be better leveraged from our Asian operations in Penang, Malaysia and Tianjin, China," said Dr. Heiner Dreismann, Lead Director and Interim CEO of GeneNews. "Transferring this segment of our operations to our Asian facilities also enhances opportunities to access to capital from Asian sources, which GeneNews has successfully secured in the past, to support research and development activities including the accrual of patient samples to support our pipeline development. We will also be better positioned to attract resources and expertise to facilitate the commercial launch of our products in China, Malaysia and the surrounding regions."

Dr. Dreismann continued: "This restructuring will result in a substantial reduction in cash expenditures in Canada over the near term and allows us to completely refocus our North American sources on the commercialization of our lead ColonSentry(TM) product in Canada and the U.S. As we roll out our test in additional regions in Canada and prepare for its commercial launch in the U.S. in the second half of 2009, we believe that a leaner and more focused organization will provide a significant strategic advantage to GeneNews."

The Company will maintain its global headquarters in Canada where it will focus on Canadian marketing activities and development of a U.S. marketing and reimbursement strategy for the ColonSentry(TM) test. GeneNews will continue development and validation of the ColonSentry(TM) test to support a CLIA submission and the operation of a centralized clinical reference laboratory to serve the North American market from its global headquarters. Scientific leadership and direction for research and development activities that will be pursued by the Company's Asian facilities and the development of a strategy to create a personalized health management system based on the Sentinel Principle(TM) will also be managed in the Company's global headquarters.

About GeneNews

--------------

GeneNews is focused on the application of functional genomics to enable early diagnosis and personalized therapeutic intervention based on disease-specific biomarkers. The Company has developed a novel approach, the Sentinel Principle(TM), to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews is currently applying the Sentinel Principle(TM) in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. For more information on GeneNews, visit http://www.genenews.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.


'/>"/>
SOURCE GeneNews Limited
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. GeneNews appoints Patrick Terry as lead strategic advisor for U.S. commercialization of ColonSentry(TM)
2. GeneNews Announces Second Quarter Results
3. GeneNews launches worlds first blood test for colorectal cancer screening
4. GeneNews announces management changes to support commercialization of ColonSentry(TM)
5. Genenews adds two members to its Board of Directors
6. GeneNews Announces First Quarter Results
7. GeneNews reports positive results from validation study of colorectal cancer biomarkers in late-breaking abstract at AACR
8. GeneNews announces 2007 year end results
9. GeneNews selected to present late-breaking abstract at AACR Annual Meeting
10. GeneNews receives ISO 13485 accreditation
11. GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... , ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension ... are higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... bottom of the cuvette holder. , FireflySci has developed several Agilent flow cell ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute approval ... of microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... the launch of the Supplyframe Design Lab . Located in Pasadena, Calif., ... the future of how hardware projects are designed, built and brought to market. ...
Breaking Biology Technology:
(Date:5/20/2016)... 20, 2016  VoiceIt is excited to announce ... By working together, VoiceIt and VoicePass ... and VoicePass take slightly different approaches to voice ... security and usability. ... new partnership. "This marketing and technology ...
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:5/3/2016)... VILNIUS, Lithuania , May 3, 2016 /PRNewswire/ ... today released the MegaMatcher Automated Biometric Identification ... deployment of large-scale multi-biometric projects. MegaMatcher ABIS can ... and accuracy using any combination of fingerprint, face ... of MegaMatcher SDK and MegaMatcher ...
Breaking Biology News(10 mins):